Resync bio to democratize ai-powered drug discovery with nvidia bionemo

San jose, calif.--(business wire)--resync bio, a technology company providing ai-enabled drug discovery solutions, today announced that it has integrated nvidia bionemo nim microservices to accelerate its scalable, high throughput ai tools for drug discovery teams. through this collaboration, resync offers seamless, no-code access to the suite of small molecule nvidia nim microservices, empowering drug discovery teams to harness advanced ai without coding expertise. the nvidia bionemo platform.
NVDA Ratings Summary
NVDA Quant Ranking